Nat Commun: Novel drug candidates may use novel uptake strategies to target cancer cells in mice

Activation of compensatory signaling nodes in cancer often requires combination therapy, which is often plagued by dose-limiting toxic side effects

In this study, researchers report a novel kinase inhibitor that may significantly reduce disease, limit toxic effects, and prolong survival in mice with myelofibrosis, a precursor to acute leukemia

Cancer therapy often involves combination therapy to target the susceptibility of different cancer cells, but because these drugs circulate in the body and are absorbed and cleared at different rates, it is possible to limit drug toxicity and side effects while limiting drug toxicity.

New drug candidates may use novel uptake strategies to target cancer cells in mice

Image credit: Danielle Dobbs/Michigan Medicine

Unlike traditional oral drugs, which are usually designed to be absorbed quickly into the bloodstream, the researchers found in mice with myelofibrosis that LP-182 was first absorbed by the lymphatic system in the gut, which It acts as a depot, separating the drug from the rest of the body and continuously releasing therapy into the general circulation of the body over time, while maintaining drug concentrations at optimal therapeutic levels

The disease spreads through lymphoid tissue, which is also a common route for cancer to metastasize, so the researchers' latest study may provide a new strategy for preventing cancer from spreading.

Late-stage investigator Ross and colleagues will continue to expand the clinical study of LP-182, aiming to conduct a phase I clinical trial in human patients with myelofibrosis, and researchers are currently developing additional lymphoid-targeting kinases Inhibitors thus treat more solid tumors such as breast, brain, gastrointestinal and pancreatic cancers, as well as autoimmune diseases such as lupus and multiple sclerosis

Original source:

Ross, BD, Jang, Y.